Literature DB >> 17579669

Global distribution of the most prevalent deletions causing hypotonia-cystinuria syndrome.

Kevin Martens1, Inge Heulens, Sandra Meulemans, Marco Zaffanello, David Tilstra, Frederik J Hes, Raoul Rooman, Inge François, Francis de Zegher, Jaak Jaeken, Gert Matthijs, John W M Creemers.   

Abstract

Hypotonia-cystinuria syndrome (HCS) is a recessive disorder caused by microdeletions of SLC3A1 and PREPL on chromosome 2p21. Patients present with generalized hypotonia at birth, failure to thrive, growth retardation and cystinuria type I. While the initially described HCS families live in small regions in Belgium and France, we have now identified HCS alleles in patients and carriers from the Netherlands, Italy, Canada and United States of America. Surprisingly, among the nine deletions detected in those patients, only one novel deletion was found. Furthermore, one previously described deletion was found six times, another twice. Finally, we have investigated the frequency of both deletions using a random Belgian cohort. Given the global occurrence, HCS should be considered in the differential diagnosis of neonatal hypotonia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579669     DOI: 10.1038/sj.ejhg.5201881

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  17 in total

1.  Calmodulin methyltransferase is an evolutionarily conserved enzyme that trimethylates Lys-115 in calmodulin.

Authors:  Roberta Magnani; Lynnette M A Dirk; Raymond C Trievel; Robert L Houtz
Journal:  Nat Commun       Date:  2010-07-27       Impact factor: 14.919

2.  First cardiac manifestation of hypotonia-cystinuria syndrome.

Authors:  Mustafa Kılıç; Ahmet Cevdet Ceylan; Utku Arman Örün; Esra Kılıç
Journal:  Metab Brain Dis       Date:  2018-04-07       Impact factor: 3.584

3.  Clinical utility gene card for: Cystinuria.

Authors:  Thomas Eggermann; Klaus Zerres; Virginia Nunes; Mariona Font-Llitjós; Luigi Bisceglia; Anthoula Chatzikyriakidou; Luca dello Strologo; Elon Pras; John Creemers; Manuel Palacin
Journal:  Eur J Hum Genet       Date:  2011-08-24       Impact factor: 4.246

4.  PREPL deficiency with or without cystinuria causes a novel myasthenic syndrome.

Authors:  Luc Régal; Xin-Ming Shen; Duygu Selcen; Chantal Verhille; Sandra Meulemans; John W M Creemers; Andrew G Engel
Journal:  Neurology       Date:  2014-03-07       Impact factor: 9.910

5.  Deletion of C2orf34, PREPL and SLC3A1 causes atypical hypotonia-cystinuria syndrome.

Authors:  B Chabrol; K Martens; S Meulemans; A Cano; J Jaeken; G Matthijs; J W M Creemers
Journal:  BMJ Case Rep       Date:  2009-02-02

6.  A substrate-free activity-based protein profiling screen for the discovery of selective PREPL inhibitors.

Authors:  Anna Mari Lone; Daniel A Bachovchin; David B Westwood; Anna E Speers; Timothy P Spicer; Virneliz Fernandez-Vega; Peter Chase; Peter S Hodder; Hugh Rosen; Benjamin F Cravatt; Alan Saghatelian
Journal:  J Am Chem Soc       Date:  2011-07-12       Impact factor: 15.419

Review 7.  Pathophysiology and treatment of cystinuria.

Authors:  Josep Chillarón; Mariona Font-Llitjós; Joana Fort; Antonio Zorzano; David S Goldfarb; Virginia Nunes; Manuel Palacín
Journal:  Nat Rev Nephrol       Date:  2010-06-01       Impact factor: 28.314

Review 8.  The second point mutation in PREPL: a case report and literature review.

Authors:  Sebastian Silva; Noriko Miyake; Carolina Tapia; Naomichi Matsumoto
Journal:  J Hum Genet       Date:  2018-02-26       Impact factor: 3.172

9.  Cooperation between NRF-2 and YY-1 transcription factors is essential for triggering the expression of the PREPL-C2ORF34 bidirectional gene pair.

Authors:  Chien-Chang Huang; Wun-Shaing Wayne Chang
Journal:  BMC Mol Biol       Date:  2009-07-03       Impact factor: 2.946

Review 10.  Nephrolithiasis related to inborn metabolic diseases.

Authors:  Pierre Cochat; Valérie Pichault; Justine Bacchetta; Laurence Dubourg; Jean-François Sabot; Christine Saban; Michel Daudon; Aurélia Liutkus
Journal:  Pediatr Nephrol       Date:  2009-01-21       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.